RS 40:1125.41
248 words·~1 min read·
/la/title-40/40-3191A research copy — for the controlling text, always check the official state or federal source. Not legal advice.
RS 40:1125.41
SUBPART E. MISCELLANEOUS PROVISIONS
§1125.41. Annual review of Medicaid coverage for sickle cell disease
A. The Louisiana Department of Health shall conduct an annual review of all medications and forms of treatment for sickle cell disease and services for enrollees with a diagnosis of sickle cell disease that are eligible for coverage under the Louisiana Medicaid program. The department shall determine if the available covered medications, treatments, and services are adequate to meet the needs of enrollees with a diagnosis of sickle cell disease and whether the department should seek to add additional medications, treatments, or services.
B. When conducting the annual review required by Subsection A of this Section, the Louisiana Department of Health shall solicit and consider input from the general public with specific emphasis on attempting to receive input from persons or groups with knowledge and experience in the area of sickle cell disease treatment.
C. On or before January 15, 2023, and on or before January fifteenth each year thereafter, the Louisiana Department of Health shall submit a report to the Senate Committee on Finance, the House Committee on Appropriations, and the Senate and House committees on health and welfare that details the department's findings from the annual review required by this Section, as well as any recommendations to the legislature based upon those findings. The department shall publish the annual report required by this Subsection on its website in a manner accessible by the general public.
Acts 2022, No. 670, §1.